Surveillance of the impact of pneumococcal conjugate vaccines in developing countries

Infection due to Streptococcus pneumoniae is a leading cause of morbidity and mortality in young children, especially in developing countries. With the support of Gavi, the Vaccine Alliance, the majority of these countries have introduced pneumococcal conjugate vaccines (PCV) into their national imm...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2016-02, Vol.12 (2), p.417-420
Main Authors: Rodgers, Gail L, Klugman, Keith P
Format: Article
Language:English
Subjects:
Adolescent
Adult
Carrier State - prevention & control
Child
Child, Preschool
Cost-Benefit Analysis
Developing Countries
Heptavalent Pneumococcal Conjugate Vaccine - economics
Heptavalent Pneumococcal Conjugate Vaccine - immunology
Humans
Immunity, Herd - immunology
Immunization Programs - economics
Pneumococcal Vaccines - economics
Pneumococcal Vaccines - immunology
Pneumonia, Pneumococcal - economics
Pneumonia, Pneumococcal - prevention & control
Streptococcus pneumoniae - immunology
Vaccination - economics
Vaccines, Conjugate - economics
Vaccines, Conjugate - immunology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infection due to Streptococcus pneumoniae is a leading cause of morbidity and mortality in young children, especially in developing countries. With the support of Gavi, the Vaccine Alliance, the majority of these countries have introduced pneumococcal conjugate vaccines (PCV) into their national immunization programs and early data demonstrate a high degree of effectiveness, translating to enormous public health benefit through both direct and indirect (herd) effects. Future vaccination strategy may be focused on maintaining herd effects rather than individual protection. Evaluation of vaccine-type carriage, particularly in pneumonia cases, may be an easy, feasible way of measuring continued vaccine impact.
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2015.1057671